Overview

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

Status:
Withdrawn
Trial end date:
2024-03-19
Target enrollment:
Participant gender:
Summary
Columbia 2 is a Phase 2 platform study to evaluate the safety and efficacy of standard of care (FOLFOX) alone and in combination with novel oncology therapies in adjuvant high-risk microsatellite-stable colorectal cancer
Phase:
Phase 2
Details
Lead Sponsor:
MedImmune LLC
Treatments:
Antibodies, Monoclonal
Durvalumab
Fluorouracil
Folic Acid
Leucovorin
Levoleucovorin
Oxaliplatin